Patient Characteristics and Utilization Patterns of Short-Acting Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) Biosimilars Compared to Their Reference Product.
Aaron B MendelsohnJames MarshallCara L McDermottPamala A PawloskiJeffrey S BrownCatherine M LockhartPublished in: Drugs - real world outcomes (2021)
New episodes of short-acting biosimilar filgrastim products have increased over time while the overall number of new users remained flat. Although barriers to biosimilar use in oncology have been noted, uptake has begun and continues to grow.